Crystal Lake, Illinois, February 17, 2022 — AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, today reported fourth quarter and annual results for 2021.
Fourth Quarter 2021 Summary
- Strong top line growth across each segment resulted in reported sales up 9% and core sales (excluding currency effects and acquisitions) up 10%
- Reported earnings per share increased 8% to $0.85
- Adjusted earnings per share (excluding restructuring charges, the unrealized loss on the equity investment and acquisition costs) increased 3% to $0.93
- Reported net income increased 8% to $58 million
- Adjusted EBITDA increased 3% to $154 million
Annual 2021 Summary
- Top line growth across each segment drove record annual sales of $3.2 billion
- Reported sales grew 10% and core sales increased 7%
- Reported earnings per share increased 12% to $3.61
- Adjusted earnings per share increased 4% to $3.88
- Reported net income totaled $244 million, exceeding 2019 pre-pandemic levels
- Adjusted EBITDA totaled $607 million, exceeding 2019 pre-pandemic levels
- Acquired Voluntis, a pioneer in digital therapeutics, and 80% of Weihai Hengyu Medical Products, a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery
- Furthered our ESG performance and commitments resulting in the following recognitions: Newsweek’s Most Responsible Companies, Barron’s Most Sustainable Companies, Forbes’ Green Growth 50 list, Forbes’ Global Top 10 Female-Friendly Companies, JUST Capital’s Top 10 Companies Leading in Reducing Environmental Impact, EcoVadis Platinum and CDP’s Supplier Engagement Leaderboard
- 28th consecutive year of paying increased annual cash dividends
